Stimulation of 5-HT2 receptors in the nucleus tractus solitarius enhances NMDA receptor-mediated reflex-evoked bradycardiac responses in the rat.
The modulation by 5-HT2 receptors in the nucleus tractus solitarius of the reflex bradycardia evoked by stimulation of peripheral baroreceptors and cardiopulmonary chemoreceptors, and their possible functional interactions with local NMDA receptors, were investigated in pentobarbital- and urethane-anaesthetized rats, respectively. Microinjection of the 5-HT2 receptor agonist, 2,5-dimethoxy-4-iodoamphetamine (0.1-0.5 pmol), into the nucleus tractus solitarius elicited a dose-dependent hypotension and bradycardia. Bilateral microinjections at the same site of a subthreshold dose of 2,5-dimethoxy-4-iodoamphetamine (0.05 pmol) significantly enhanced the aforementioned reflex-evoked bradycardiac responses. In contrast, local bilateral microinjections of the NMDA receptor antagonist, 2-amino-5-phosphonopentanoic acid (500 and 1000 pmol), reduced, in a dose-dependent manner, both reflex-evoked responses. The facilitatory effect of 2,5-dimethoxy-4-iodoamphetamine upon these reflex-evoked bradycardiac responses was prevented by prior local microinjection of low doses of either the selective 5-HT2 receptor antagonist, ketanserin (10 pmol), or 2-amino-5-phosphonopentanoic acid (100 pmol), which, on their own, did not affect the reflex-associated bradycardia. These data suggest that 5-HT2 receptors within the nucleus tractus solitarius participate in a facilitatory modulation of the reflex control of heart rate, probably through functional interactions with local NMDA receptors.
N'Diaye
A
A
Institut National de la Santé et de la Recherche Médicale, Unité 288, Centre Hospitalo-Universitaire Pitié-Salpêtrière, Paris, France.
Sévoz-Couche
C
C
Nosjean
A
A
Hamon
M
M
Laguzzi
R
R
D015763:2-Amino-5-phosphonovalerate / Q000494:pharmacology; D000662:Amphetamines / Q000494:pharmacology; D000758:Anesthesia; D000818:Animals; D001794:Blood Pressure; D001919:Bradycardia / Q000503:physiopathology*; D002628:Chemoreceptor Cells / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D006339:Heart Rate; D007650:Ketanserin / Q000494:pharmacology; D008297:Male; D008845:Microinjections; D010656:Phenylephrine / Q000494:pharmacology; D011311:Pressoreceptors / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism*; D011985:Receptors, Serotonin / Q000378:metabolism*; D012018:Reflex / Q000187:drug effects / Q000502:physiology*; D012701:Serotonin / Q000378:metabolism; D012702:Serotonin Antagonists / Q000494:pharmacology; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D017552:Solitary Nucleus / Q000502:physiology*; D013566:Sympathomimetics / Q000494:pharmacology
D000662:Amphetamines; D018691:Excitatory Amino Acid Antagonists; D016194:Receptors, N-Methyl-D-Aspartate; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; D013566:Sympathomimetics; D010656:Phenylephrine; D012701:Serotonin; D015763:2-Amino-5-phosphonovalerate; D007650:Ketanserin; C015952:4-iodo-2,5-dimethoxyphenylisopropylamine